Edwards Lifesciences (EW) Interest Expenses (2009 - 2026)

Edwards Lifesciences' Interest Expenses history runs 18 years deep, the most recent figure standing at $400.2 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 8.93% year-over-year to $400.2 million in Q1 2026; TTM through Mar 2026 was $400.2 million, a 8.93% increase from a year earlier, with the FY2025 full-year figure at $390.4 million, up 8.78% from the prior year.
• Interest Expenses advanced to $400.2 million in Q1 2026 per EW's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Interest Expenses topped out at $400.2 million in Q1 2026 and bottomed at -$1.7 million in Q4 2025.
• The 5-year median for Interest Expenses is $314.9 million (2023), against an average of $250.1 million.
• Across the five-year window, Interest Expenses jumped 687.18% in 2022 and plunged 103.76% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $22.9 million in 2022, then soared by 39.3% to $31.9 million in 2023, then slumped by 103.76% to -$1.2 million in 2024, then plunged by 41.67% to -$1.7 million in 2025, then surged by 23641.18% to $400.2 million in 2026.
• Per Business Quant, the three latest EW Interest Expenses figures stand at $400.2 million (Q1 2026), -$1.7 million (Q4 2025), and $384.3 million (Q3 2025).